Compare MKC & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MKC | GH |
|---|---|---|
| Founded | 1889 | 2011 |
| Country | United States | United States |
| Employees | 14100 | N/A |
| Industry | Packaged Foods | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.3B | 13.3B |
| IPO Year | N/A | 2018 |
| Metric | MKC | GH |
|---|---|---|
| Price | $51.48 | $89.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 19 |
| Target Price | $67.00 | ★ $119.79 |
| AVG Volume (30 Days) | ★ 5.1M | 2.1M |
| Earning Date | 03-31-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $982,021,000.00 |
| Revenue This Year | $16.24 | $33.30 |
| Revenue Next Year | $3.71 | $28.27 |
| P/E Ratio | $23.90 | ★ N/A |
| Revenue Growth | N/A | ★ 32.88 |
| 52 Week Low | $47.52 | $36.36 |
| 52 Week High | $78.03 | $120.74 |
| Indicator | MKC | GH |
|---|---|---|
| Relative Strength Index (RSI) | 39.99 | 50.09 |
| Support Level | $47.52 | $82.33 |
| Resistance Level | $69.16 | $90.28 |
| Average True Range (ATR) | 1.46 | 5.39 |
| MACD | 0.38 | 0.55 |
| Stochastic Oscillator | 37.15 | 59.57 |
In its 135-plus-year history, McCormick has become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond consumers, McCormick's customer base includes quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers. Its reach is extensive, with nearly 40% of sales generated beyond its home turf to 150 countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and Cholula, among others.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.